Profile data is unavailable for this security.
About the company
Bajaj Healthcare Limited is an India-based pharmaceutical company. The Company is engaged in activities of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), bulk drugs, branded and generic formulations. It is focused on development, manufacturing and supply of amino acids, nutritional supplements and API for pharmaceutical, nutraceuticals and food industries. It operates through three segments: APIs, Finished Dosage Formulations (FDFs), and Intermediates. Its APIs include Ascorbic Acid IP, Sodium Ascorbate, Ferrous Ascorbate, and others. Its Intermediary products include Calcium Phosphoryl Choline Chloride (CPCC) and Chlorhexidine (CH Base). It offers a range of FDFs forms, including tablets, caplets, capsules, and oral powders, all available in bulk quantities. The FDFs products include Cholecalciferol Sachet, Ticagrelor Tablet, Pancreatin Capsules, levofloxacin Tablets IP, Bisacodyl Tablet IP, and others.
- Revenue in INR (TTM)4.76bn
- Net income in INR-133.27m
- Incorporated1993
- Employees944.00
- LocationBajaj Healthcare Ltd202-204Faiz-E-Qutbi, 375,Narshi Natha StreetTHANE 400604IndiaIND
- Phone+91 2 240177400
- Fax+91 2 266177458
- Websitehttp://www.bajajhealth.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Albert David Ltd | 3.60bn | 707.73m | 8.12bn | 1.50k | 11.51 | -- | 10.51 | 2.26 | 124.02 | 124.02 | 630.61 | -- | -- | -- | -- | 2,403,949.00 | -- | 10.00 | -- | 13.15 | 65.26 | 59.85 | 19.67 | 11.87 | -- | 83.07 | -- | 12.89 | 6.12 | 2.72 | 108.49 | 33.59 | 40.87 | 13.90 |
| Wanbury Ltd | 5.60bn | 523.05m | 8.29bn | 1.49k | 16.28 | -- | 12.66 | 1.48 | 15.54 | 15.54 | 168.35 | -- | -- | -- | -- | 3,759,038.00 | -- | 11.63 | -- | -- | 49.35 | 42.46 | 9.33 | 7.62 | -- | 1.76 | -- | -- | 15.21 | 8.02 | 638.26 | -- | 29.87 | -- |
| Nectar Lifesciences Ltd | 16.49bn | 61.44m | 8.62bn | 1.69k | 142.13 | -- | 13.09 | 0.5315 | 0.275 | 0.275 | 73.96 | -- | -- | -- | -- | 9,782,218.00 | -- | -0.2956 | -- | -0.541 | 29.64 | 16.49 | 0.3725 | -0.4053 | -- | 1.06 | -- | -- | 10.53 | -9.56 | 120.66 | -36.29 | -5.06 | -- |
| Bajaj Healthcare Ltd | 4.76bn | -133.27m | 11.86bn | 944.00 | -- | -- | 81.44 | 2.52 | -4.82 | -10.30 | 172.62 | -- | -- | -- | -- | 5,041,608.00 | -- | 7.67 | -- | 14.11 | 48.43 | 33.26 | -2.80 | 7.99 | -- | 1.74 | -- | 4.90 | -26.69 | 5.04 | -122.55 | -- | 15.08 | -- |
| Jagsonpal Pharmaceuticals Ltd | 2.10bn | 203.13m | 12.34bn | 1.03k | 62.04 | -- | 54.87 | 5.92 | 7.57 | 7.57 | 78.03 | -- | -- | -- | -- | 2,048,663.00 | -- | 10.95 | -- | 13.29 | 56.41 | 58.13 | 9.67 | 9.21 | -- | 26.27 | -- | 43.81 | -11.83 | 4.58 | -15.94 | 25.50 | -35.69 | 82.06 |
| Ngl Fine Chem Ltd | 3.58bn | 420.29m | 12.80bn | 390.00 | 31.26 | -- | 34.06 | 3.67 | 68.03 | 68.03 | 580.00 | -- | -- | -- | -- | 9,188,328.00 | -- | 15.06 | -- | 19.58 | 52.02 | 43.53 | 11.73 | 13.15 | -- | 26.59 | -- | 3.06 | 21.79 | 17.20 | 101.58 | 15.47 | 14.49 | 0.00 |
| Bliss GVS Pharma Ltd | 7.94bn | 814.66m | 13.39bn | 831.00 | 16.78 | -- | 11.59 | 1.70 | 7.63 | 7.63 | 74.93 | -- | -- | -- | -- | 9,559,162.00 | -- | 6.46 | -- | 8.22 | 51.81 | 43.91 | 11.24 | 9.92 | -- | -- | -- | 7.92 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| Lincoln Pharmaceuticals Ltd | 5.92bn | 979.63m | 13.74bn | 1.70k | 13.96 | -- | 12.52 | 2.31 | 48.91 | 48.91 | 295.69 | -- | -- | -- | -- | 3,483,600.00 | -- | 13.95 | -- | 16.54 | 51.92 | 50.65 | 16.54 | 14.71 | -- | 60.93 | -- | 3.44 | 13.76 | 9.66 | 27.99 | 13.88 | 21.54 | 3.71 |
| Kopran Ltd | 6.37bn | 592.79m | 14.25bn | 358.00 | 20.18 | -- | 19.42 | 2.22 | 14.53 | 14.53 | 150.01 | -- | -- | -- | -- | 17,794,040.00 | -- | 8.47 | -- | 12.23 | 36.03 | 32.93 | 9.31 | 8.89 | -- | 27.17 | -- | 25.41 | 11.54 | 11.42 | 87.11 | 16.23 | 12.53 | -- |
| JG Chemicals Ltd | -100.00bn | -100.00bn | 15.33bn | 56.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -14.90 | -- | -43.84 | -- | -- | -- |
| Remus Pharmaceuticals Ltd | 2.12bn | 215.37m | 15.51bn | 48.00 | 72.97 | 18.48 | 59.74 | 7.55 | 37.34 | 37.34 | 374.91 | 147.42 | 1.46 | 7.61 | 3.56 | 44,270,750.00 | 17.80 | -- | 44.48 | -- | 22.67 | -- | 12.22 | -- | 1.12 | 55.56 | 0.0997 | -- | 371.94 | -- | 153.29 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Motilal Oswal Asset Management Co. Ltd.as of 30 Jun 2024 | 126.00 | 0.00% |
